Meeting
2014 ASCO Annual Meeting
MINT: Multi-institutional, neoadjuvant therapy MammaPrint project.
Authors
Charles E. Cox
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Charles E. Cox , Peter William Blumencranz , Ruben A. Saez , Robert Wesolowski , William C. Dooley , Lisette Stork , Femke De Snoo , Jessica Gibson , Eli Avisar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Clinical Trial Registration Number
NCT01501487
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS1137)
DOI
10.1200/jco.2014.32.15_suppl.tps1137
Abstract #
TPS1137
Poster Bd #
228B
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
The prospective MammaPrint MINT (Multi-Institutional Neo-adjuvant Therapy) study.
First Author: Charles E. Cox
Poster
2023 ASCO Annual Meeting
The proliferation biomarker SPAG5 expression in HER2 low and HER2 overexpression early breast cancer (BC) predicting tumour response to neoadjuvant chemotherapy (NACT) with and without trastuzumab.
First Author: Tarek Mohamed Ahmed Abdel-Fatah
Poster
2023 ASCO Annual Meeting
Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers.
First Author: Sara P. Myers
Poster
2023 ASCO Annual Meeting
MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST.
First Author: Peter D. Beitsch